<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04300114</url>
  </required_header>
  <id_info>
    <org_study_id>SHR3162-III-304</org_study_id>
    <nct_id>NCT04300114</nct_id>
  </id_info>
  <brief_title>A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy</brief_title>
  <official_title>A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Fluzoparib Monotherapy in Patients With gBRCA/PALB2 Mutated Metastatic Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to evaluate the tolerability, safety and efficacy of maintenance
      Fluzoparib monotherapy in patients with gBRCA/PALB2 mutated metastatic pancreatic cancer
      whose disease has not progressed on first line platinum based chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS by Blinded Independent Central Review (BICR) Using RECIST v1.1</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Progression-Free-Survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR by BICR Using RECIST v1.1</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Objective Response Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR by BICR Using RECIST v1.1</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Disease Control Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DoR by BICR Using RECIST v1.1</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Duration of Response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS by Investigators Using RECIST v1.1</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Progression-Free-Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR by Investigators Using RECIST v1.1</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Objective Response Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR by Investigators Using RECIST v1.1</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Disease Control Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DoR by Investigators Using RECIST v1.1</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Duration of Response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Overall-Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-emergent adverse events</measure>
    <time_frame>From the first drug administration to within 30 days for the last drug dose</time_frame>
    <description>The number and proportion of subjects experiencing treatment-emergent adverse events (TEAE)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Metastatic Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Maintenance Fluzoparib monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance placebo monotherapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluzoparib</intervention_name>
    <description>Fluzoparib capsules po. 150 mg twice daily</description>
    <arm_group_label>Maintenance Fluzoparib monotherapy</arm_group_label>
    <other_name>SHR3162</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules po. twice daily</description>
    <arm_group_label>Maintenance placebo monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Aged ≥ 18 years.

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1

          -  Expected survival ≥ 3 months.

          -  Histologically or cytologically confirmed metastatic pancreas adenocarcinoma.

          -  Patients who have received a minimum of 16 weeks of continuous platinum treatment for
             metastatic disease and have no evidence of progression based on investigator's
             opinion.

          -  Patients with measurable disease and/or non-measurable or no evidence of disease
             assessed at baseline by CT or MRI.

          -  Documented mutation in germline BRCA1/2 or PALB2 that is predicted to be deleterious
             or suspected deleterious.

          -  Adequate organ performance based on laboratory blood tests.

          -  Women of childbearing potential and men must agree to use adequate contraception prior
             to study entry and for the duration of study participation.

          -  Ability to understand and the willingness to sign a written informed consent document.

        Major Exclusion Criteria:

          -  Previous treatment with a poly ADP-ribose polymerase (PARP) inhibitor.

          -  Patients who have had radiotherapy within 2 weeks or participated in another clinical
             trial with any investigational agents within 2 weeks prior to study screening.

          -  Previous treatment using CYP3A4 inducers within 3 weeks or inhibitors within 2 weeks.

          -  Significant cardiovascular disease such as New York Heart Associate Class III/IV,
             cardiac failure, myocardial infarction, unstable arrhythmia, or evidence of ischemia
             on ECG within 6 months prior to enrolment.

          -  Patients unable to swallow orally administered medication and patients with
             gastrointestinal disorders likely to interfere with absorption of the study
             medication.

          -  Patients with myelodysplastic syndrome/acute myeloid leukaemia.

          -  Known active hepatitis B or C infection.

          -  History of immunodeficiency (including HIV infection) or organ transplantation.

          -  Other serious accompanying illnesses, which, in the researcher's opinion, could
             seriously adversely affect the safety of the treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yupei Zhao, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chunlei Jin, Ph.D</last_name>
    <phone>86-021-23511999</phone>
    <email>jinchunlei@hrglobe.cn</email>
  </overall_contact>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 5, 2020</study_first_submitted>
  <study_first_submitted_qc>March 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2020</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

